Cargando…

Incidence and predictors for chemotherapy modifications and their impact on the outcome of ovarian cancer patients

PURPOSE: Chemotherapy (CTX) is an important part of the treatment strategy of stage II–IV ovarian cancer. CTX modifications, such as delays, dose reductions or premature terminations might have a negative impact on overall survival (OS) and progression free survival (PFS). The goal of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hatsy, Sandra, Brambs, Christine, Kiechle, Marion
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Gynecologic Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147744/ https://www.ncbi.nlm.nih.gov/pubmed/36326848 http://dx.doi.org/10.1007/s00404-022-06813-9

Ejemplares similares

TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge
por: Grill, Sabine, et al.
Publicado: (2020)

Intracavitary brachytherapy with additional Heyman capsules in the treatment of cervical cancer
por: Scharl, Sophia, et al.
Publicado: (2022)

Demand for integrative medicine among women with breast and gynecological cancer: a multicenter cross-sectional study in Southern and Northern Germany
por: Grimm, Donata, et al.
Publicado: (2020)

First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer
por: Ettl, Johannes, et al.
Publicado: (2020)

The importance of the Peritoneal Cancer Index (PCI) to predict surgical outcome after neoadjuvant chemotherapy in advanced ovarian cancer
por: Rawert, Friederike Luise, et al.
Publicado: (2022)

CD34 and Bcl-2 as predictors for the efficacy of neoadjuvant chemotherapy in cervical cancer
por: Lin, Yun, et al.
Publicado: (2021)

The impact of Enhanced Recovery after Surgery (ERAS) pathways with regard to perioperative outcome in patients with ovarian cancer
por: Reuter, Susanne, et al.
Publicado: (2021)

Prognostic values of DNA mismatch repair genes in ovarian cancer patients treated with platinum-based chemotherapy
por: Zhao, Chuchu, et al.
Publicado: (2017)

Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome
por: Hall, Marcia, et al.
Publicado: (2019)

Lifestyle modifications after the diagnosis of gynecological cancer
por: Paepke, Daniela, et al.
Publicado: (2021)

Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
por: Glajzer, Jacek, et al.
Publicado: (2022)

Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases
por: Di Giorgio, Angelo, et al.
Publicado: (2016)

Impact of age on indication for chemotherapy in early breast cancer patients: results from 104 German institutions from 2008 to 2017
por: Hoffmann, Ann Sophie, et al.
Publicado: (2023)

Second fertility-sparing surgery and fertility-outcomes in patients with recurrent borderline ovarian tumors
por: Wang, Lifei, et al.
Publicado: (2022)

Evaluation of selected ultrasonographic parameters and marker levels in the preoperative differentiation of borderline ovarian tumors and ovarian cancers
por: Sobiczewski, Piotr, et al.
Publicado: (2012)

Cytoreductive Surgery Under Aminolevulinic Acid-Mediated Photodynamic Diagnosis Plus Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Carcinomatosis from Ovarian Cancer and Primary Peritoneal Carcinoma: Results of a Phase I Trial
por: Liu, Yang, et al.
Publicado: (2014)

The sL1CAM in sera of patients with endometrial and ovarian cancers
por: Wojciechowski, Michał, et al.
Publicado: (2016)

Pelvic lymphadenectomy in vulvar cancer and its impact on prognosis and outcome
por: Jaeger, A., et al.
Publicado: (2021)

Factors influencing the time to surgery after neoadjuvant chemotherapy in breast cancer patients
por: Müller, Carolin, et al.
Publicado: (2020)

Influences on pathologic complete response in breast cancer patients after neoadjuvant chemotherapy
por: Müller, Carolin, et al.
Publicado: (2021)

Experience with oral emergency contraception since the OTC switch in Germany
por: Kiechle, Marion, et al.
Publicado: (2016)

Improving ovarian cancer imaging with LHRH-NBs: an experimental study
por: Li, Wenjuan, et al.
Publicado: (2016)

Role of integrins in the metastatic spread of high-grade serous ovarian cancer
por: Krajnak, Slavomir, et al.
Publicado: (2021)

Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer
por: Cornali, Tommaso, et al.
Publicado: (2017)

Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue
por: Peters, Inge T. A., et al.
Publicado: (2016)

Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
por: Bieg, Dominik, et al.
Publicado: (2018)

Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2020)

The role of resveratrol, Sirtuin1 and RXRα as prognostic markers in ovarian cancer
por: Chen, Fangfang, et al.
Publicado: (2021)

Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer
por: Penson, Richard T, et al.
Publicado: (2023)

A machine learning approach applied to gynecological ultrasound to predict progression-free survival in ovarian cancer patients
por: Arezzo, Francesca, et al.
Publicado: (2022)

Nomogram for predicting postoperative cancer-specific early death in patients with epithelial ovarian cancer based on the SEER database: a large cohort study
por: Zhang, Tingting, et al.
Publicado: (2021)

A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum‐Sensitive Ovarian Cancer
por: Pignata, Sandro, et al.
Publicado: (2021)

Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10
por: Drew, Yvette, et al.
Publicado: (2019)

Surgery due to mechanical bowel obstruction in relapsed ovarian cancer: clinical and surgical results of a bicentric analysis of 87 patients
por: Armbrust, R., et al.
Publicado: (2021)

Influence of interdisciplinary frailty screening on perioperative complication rates in elderly ovarian cancer patients: results of a retrospective observational study
por: Anic, Katharina, et al.
Publicado: (2022)

GBAS Regulates the Proliferation and Metastasis of Ovarian Cancer Cells by Combining with eEF1A1
por: Ning, Xin, et al.
Publicado: (2022)

Risk Factors for Anastomotic Leakage in Advanced Ovarian Cancer Surgery: A Large Single-Center Experience
por: Costantini, Barbara, et al.
Publicado: (2022)

Health Disparities in Ovarian Cancer: Report From the Ovarian Cancer Evidence Review Conference
por: Mei, Shirley, et al.
Publicado: (2023)

Successful management of mucinous ovarian cancer by conservative surgery in week 6 of pregnancy: case report and literature review
por: He, Shan-yang, et al.
Publicado: (2012)

MiR-424-3p suppresses galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
por: Bieg, Dominik, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7m88erno1rsd8s24gk730bvbe5